The Beat Ideas: Strides Pharma~ A Growth Play Post OneSource Demerger
​Strides Pharma's record growth in the US, high-ticket generics, and spin-off of OneSource CDMO set the stage for profitability recovery and long...
859 Views
Event Driven: Demerger of OneSource: A Multi-Modality CDMO
​OneSource poised for growth in the booming GLP-1 drug market, projecting revenue of $350-$400 million by 2024 with strong EBITDA margin and...
783 Views
Rubicon Research Pre-IPO - Robust Product Development Pipeline Driving Revenue Growth
Rubicon Research Limited is looking to raise about US$130m in its India IPO. In this note, we talk about the company’s historical performance.
534 Views
Strides Pharma Science: Unanticipated De-Growth Across Markets..
Strides reported a weak quarter witnessing a de-growth across revenues of 12% YoY to Rs.688cr during Q1FY22 owing to major sector headwinds such as...
228 Views
India Small Caps: Position for Outperformance Vs Large & Mid Caps
Late Friday evening, the Securities and Exchange Board of IndianÂ
765 Views